Wedbush Reiterates an 'Outperform' on Pharmacyclics (PCYC); Expect Ibrutinib to Dominate CLL Treatment
Go back to Wedbush Reiterates an 'Outperform' on Pharmacyclics (PCYC); Expect Ibrutinib to Dominate CLL Treatment| Pharmacyclics, Inc. (NASDAQ: PCYC) | Delayed: 261.25 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $261.25 | 52 Week High | $261.68 | |||
| Open | $0.82 | 52 Week Low | $85.50 | |||
| Day High | $261.25 | P/E | 300.29 | |||
| Day Low | $261.25 | EPS | $0.87 | |||
| Volume | 3,226 | |||||
